Nucleic acid-based therapy for coronavirus disease 2019

dc.creatorPiyush, Ravikant
dc.creatorRajarshi, Keshav
dc.creatorChatterjee, Aroni
dc.creatorKhan, Rajni
dc.creatorRay, Shashikant
dc.date.accessioned2020-10-06T20:10:09Z
dc.date.available2020-10-06T20:10:09Z
dc.date.issued2020-09
dc.description.abstractThe coronavirus disease 2019 (COVID-19), the pandemic that originated in China has already spread into more than 190 countries, resulting in huge loss of human life and many more are at the stake of losing it; if not intervened with the best therapeutics to contain the disease. For that aspect, various scientific groups are continuously involved in the development of an effective line of treatment to control the novel coronavirus from spreading rapidly. Worldwide scientists are evaluating various biomolecules and synthetic inhibitors against COVID-19; where the nucleic acid-based molecules may be considered as potential drug candidates. These molecules have been proved potentially effective against SARS-CoV, which shares high sequence similarity with SARS-CoV-2. Recent advancements in nucleic acid-based therapeutics are helpful in targeted drug delivery, safely and effectively. The use of nucleic acid-based molecules also known to regulate the level of gene expression inside the target cells. This review mainly focuses on various nucleic acid-based biologically active molecules and their therapeutic potentials in developing vaccines for SARS-CoV-2.pt_BR
dc.identifier.citationPIYUSH, R. et al. Nucleic acid-based therapy for coronavirus disease 2019. Heliyon, [S.l.], v. 6, n. 9, Sept. 2020.pt_BR
dc.identifier.urihttps://repositorio.ufla.br/handle/1/43329
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S2405844020318508pt_BR
dc.languageen_USpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceHeliyonpt_BR
dc.subjectMicrobiologypt_BR
dc.subjectBiotechnologypt_BR
dc.subjectMolecular biologypt_BR
dc.subjectEpidemiologypt_BR
dc.subjectVirologypt_BR
dc.subjectRegenerative medicinept_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectNucleic acid based therapypt_BR
dc.subjectSmall Interfering RNA (siRNA)pt_BR
dc.subjectRibozymespt_BR
dc.subjectDNAzymespt_BR
dc.subjectAptamerspt_BR
dc.subjectAntisensept_BR
dc.subjectOligonucleotidept_BR
dc.titleNucleic acid-based therapy for coronavirus disease 2019pt_BR
dc.typeArtigopt_BR

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
license.txt
Tamanho:
953 B
Formato:
Item-specific license agreed upon to submission
Descrição: